Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals 105

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 105

Open Medscience

AUGUST 11, 2024

Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Patient Care Disease 52

Radiology Business

NOVEMBER 5, 2024

CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.

Diagnostic Imaging 111

Diagnostic Imaging Medicare Radiopharmaceuticals Diagnostic 111

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 98

Radiopharmaceuticals Imaging Pharmaceutical Disease 98

Radiology Business

JULY 14, 2023

The agency issued its solicitation as part of the 2024 Hospital Outpatient Prospective Payment System proposed rule, released late Thursday.

Radiopharmaceuticals 98

Radiopharmaceuticals Diagnostic Hospital IT 98

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 98

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 98

Imaging Technology

DECEMBER 6, 2023

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.

Diagnostic 105

Diagnostic Diagnostic Imaging Clinic Radiopharmaceuticals 105

Open Medscience

JANUARY 1, 2024

Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications. The post Zirconium Radiopharmaceuticals in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Open Medscience

NOVEMBER 17, 2023

Gallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology. The post Gallium Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Radiology Business

JUNE 28, 2024

One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.

Radiopharmaceuticals 105

Radiopharmaceuticals Diagnostic 105

Open Medscience

DECEMBER 31, 2023

Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities. The post Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Diagnostic Medical Imaging 59

Imaging Technology

JULY 11, 2023

We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By

Radiopharmaceuticals 75

Radiopharmaceuticals Imaging Pharmaceutical Disease 75

Radiology Business

NOVEMBER 20, 2024

The Australian company will secure exclusive worldwide rights to a suite of diagnostic and therapeutic candidates geared toward urological cancers.

Radiopharmaceuticals 105

Radiopharmaceuticals Imaging Diagnostic 105

Open Medscience

JANUARY 11, 2024

Theranostics merges diagnostics and therapy, revolutionising personalised medicine with genetic profiling and targeted treatment strategies. The post Theranostics Bridging Diagnostics and Therapy for Targeted Treatment appeared first on Open Medscience.

Diagnostic 115

Diagnostic Radiopharmaceuticals Medical Imaging 115

AuntMinnie

JULY 10, 2024

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Imaging Medicare 122

Open Medscience

NOVEMBER 11, 2023

Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology. The post Exploring Copper Radiopharmaceuticals: Innovations and Applications in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Open Medscience

NOVEMBER 12, 2023

Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications. The post Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Imaging Technology

NOVEMBER 7, 2024

Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures.

Nuclear Medicine 97

Nuclear Medicine Radiopharmaceuticals Medicare Diagnostic 97

Imaging Technology

JULY 5, 2024

68Ga-DOTA-RM2 will be used as a companion diagnostic. While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate,” said Brian Markison, Lantheus CEO.

Diagnostic 105

Diagnostic Radiopharmaceuticals Disease IT 105

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

JUNE 21, 2023

POSLUMA is now commercially available through multiple radiopharmacies of PETNET Solutions, the primary manufacturer and commercial distributor for Blue Earth Diagnostics in the United States. Chief Executive Officer of Blue Earth Diagnostics Ltd. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075.

Diagnostic 97

Diagnostic Radiopharmaceuticals Imaging Medicare 97

Diagnostic Imaging

JANUARY 12, 2024

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

Radiopharmaceuticals 121

Radiopharmaceuticals 121

Imaging Technology

SEPTEMBER 27, 2023

Chief Executive Officer of Blue Earth Diagnostics. Blue Earth Diagnostics will also host an Industry-Expert Theater event, ‘POSLUMA: Precision PET Imaging that is Truly Revealing’.” from October 1 to 4, 2023. Gauden , D.Phil., PET in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Presenter: Ashesh B.

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

Imaging Technology

APRIL 5, 2024

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

Radiopharmaceuticals 52

Radiopharmaceuticals Radiation Oncology Radiation Quality and Compliance 52

Imaging Technology

JULY 28, 2023

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

Diagnostic Imaging

JUNE 28, 2023

discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.

Radiopharmaceuticals 58

Radiopharmaceuticals Nuclear Medicine Imaging 58

AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. At the time, their cancer center served a significant cancer population in the region and maintained robust and ever-expanding PET diagnostics.

Nuclear Medicine 106

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 106

AuntMinnie

SEPTEMBER 30, 2024

A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. Nearly 80% of patients in our study were progression-free after six months," he said.

Radiation Oncology 120

Radiation Oncology Radiopharmaceuticals Radiation Clinic 120

Imaging Technology

JUNE 10, 2024

For over three decades, Anderson’s pioneering research has laid the foundation for the growth of radiometal-based agents for diagnostic imaging and targeted radionuclide therapy of cancer, a field now known as "theranostics." Louis , Missouri, where she worked more than 20 years developing PET and radiopharmaceutical therapy agents.

Nuclear Medicine 104

Nuclear Medicine Radiopharmaceuticals Disease Imaging 104

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 106

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 106

Imaging Technology

JANUARY 5, 2024

milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Nuclear Medicine Pharmaceutical 52

Imaging Technology

APRIL 3, 2023

produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

AuntMinnie

OCTOBER 17, 2023

Blue Earth Diagnostics and Sinotau Pharmaceutical have signed an agreement to distribute Blue Earth's Posluma (flotufolastat F-18) PET radiotracer in China.

Pharmaceutical 52

Pharmaceutical Diagnostic Radiopharmaceuticals 52

AuntMinnie

APRIL 4, 2024

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

Radiopharmaceuticals 95

Radiopharmaceuticals Imaging Disease Diagnostic 95

Imaging Technology

JULY 25, 2024

Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. This agreement could be instrumental to the radiopharmaceutical industry and patient health. a subsidiary of BWX Technologies, Inc.

Medical 105

Medical Radiopharmaceuticals Pharmaceutical Clinic 105

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.

Clinic 98

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 98